GlaxoSmithKline PLC ADR (GSK)

JP Morgan analyst Zain Ebrahim has maintained a Sell rating on GSK plc, keeping the target price unchanged at GBX 1700. This news comes as GSK advances its mRNA flu vaccine candidate to Phase III trials after positive Phase II data. GSK is the world's second-largest pharmaceutical group, with significant sales in pharmaceutical products, OTC medicine, and vaccines.

GSK PLC (GSK) shares fell by 2.50% on Thursday, closing at £18.52, while the broader FTSE 100 Index also declined by 0.79%. The company's stock is now 18.84% below its 52-week high of £22.82, which was reached on February 18th.

GSK's hepatitis B therapy, bepirovirsen (Hibsago), has received the first global approval from Japan's MHLW, making it the first functional cure for chronic hepatitis B on the market. This approval is based on positive Phase III trial results where 19% of patients achieved a functional cure. Analysts predict Hibsago will achieve blockbuster status by 2034, contributing significantly to the growing chronic hepatitis B market.

A national survey of over 1,200 healthcare professionals by GSK found that patient hesitancy, access challenges, and systemic barriers are limiting adult vaccination rates in the US. The study highlights issues like reimbursement complexities, staffing shortages, and fragmented immunization records, emphasizing the need for targeted strategies rather than a one-size-fits-all approach to improve vaccine access and uptake. Understanding HCP perspectives is crucial for developing effective solutions to support both providers and patients in increasing vaccination rates.

GSK announced that the US FDA has accepted Jemperli (dostarlimab) for priority review for previously untreated stage II and III dMMR/MSI-H locally advanced rectal cancer, with a PDUFA action date of February 2027. The submission is supported by positive data from the AZUR-1 trial, which showed a significant and sustained clinical complete response, potentially eliminating the need for chemotherapy, radiation, and surgery for some patients. This application was also accepted under Project Orbis, an initiative that could expedite regulatory approvals.